The 1 April 2015 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. The Schedule includes the following new/revised entries:

• Abacavir sulfate with dolutegravir sodium and lamivudine (Triumeq) - new combination product
• Alemtuzumab (Lemtrada) - new medicine
• Apomorphine hydrochloride (Apomine) - new strength
• Certolizumab pegol (Cimzia) - new indication
• Dapagliflozin propanediol monohydrate (Forxiga) - new indication
• Everolimus (Afinitor) - new indication
• Iron sucrose (Venofer) - restriction change
• Mesalazine (Pentasa) - new strength
• Ofatumumab acetate (Arzerra) - new medicine
• Sorafenib tosylate (Nexavar) - new indication
• Sucroferric oxyhydroxide (Velphoro) - new medicine

For more details, go to: http://www.pbs.gov.au/browse/changes